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Abstract
Background: Prostate cancer (PCa) is the second most common disease among men
worldwide. It is important to know survival outcomes and prognostic factors for this
disease. Recruitment for the largest therapeutic randomised controlled trial in PCa—the
SystemicTherapy inAdvancingorMetastatic Prostate Cancer: Evaluation ofDrugEfficacy:
A Multi-Stage Multi-Arm Randomised Controlled Trial (STAMPEDE)—includes men with
newly diagnosed metastatic PCa who are commencing long-term androgen deprivation
therapy (ADT); the control arm provides valuable data for a prospective cohort.
Objective: Describe survival outcomes, along with current treatment standards and
factors associated with prognosis, to inform future trial design in this patient group.
Design, setting, and participants: STAMPEDE trial control arm comprising men newly
diagnosed with M1 disease who were recruited between October 2005 and January 2014.
Outcome measurements and statistical analysis: Overall survival (OS) and failure-free
survival (FFS) were reported by primary disease characteristics using Kaplan-Meier
methods. Hazard ratios and 95% conﬁdence intervals (CIs) were derived frommultivari-
ate Cox models.
Results and limitations: A cohort of 917 men with newly diagnosed M1 disease was
recruited to the control arm in the speciﬁed interval. Median follow-up was 20 mo.
Median age at randomisation was 66 yr (interquartile range [IQR]: 61–71), and median
prostate-speciﬁc antigen level was 112 ng/ml (IQR: 34–373). Most men (n = 574; 62%)
had bone-onlymetastases, whereas 237 (26%) had both bone and soft tissuemetastases;
soft tissue metastasis was foundmainly in distant lymph nodes. There were 238 deaths,
202 (85%) from PCa. Median FFS was 11 mo; 2-yr FFS was 29% (95% CI, 25–33). Median
OS was 42 mo; 2-yr OS was 72% (95% CI, 68–76). Survival time was inﬂuenced by* Corresponding author. Ni
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performance status, age, Gleason score, and metastases distribution. Median survival
after FFS event was 22 mo. Trial eligibility criteria meant men were younger and ﬁtter
than general PCa population.
Conclusions: Survival remains disappointing inmen presentingwithM1diseasewho are
started on only long-termADT, despite active treatments being available at ﬁrst failure of
ADT. Importantly, menwithM1 disease now spend themajority of their remaining life in
a state of castration-resistant relapse.
Patient summary: Results from this control arm cohort found survival is relatively short
and highly inﬂuenced by patient age, ﬁtness, and where prostate cancer has spread in the
body.
# 2014 The Authors. Published by Elsevier B.V. on behalf of European Association
of Urology. This is an open access article under the CC BY license (http://creativecom-
mons.org/licenses/by/3.0/).
Key trial eligibility criteria: 
High-risk, newly diagnosed, nonmetastac, node-negave disease 
or 
Newly diagnosed metastac or node-posive disease 
or 
Previously treated with radical surgery and/or radiotherapy, now relapsing 
and 
Fit for all protocol treatment and follow-up
Allocated to control arm 
n = 1716 
Allocated to research arms 
n = 3556 
Metastac 
n = 976 
Nonmetastac 
n = 740 
Randomised by 7-January-
2014, N = 5272
Newly diagnosed within 
6 mo before 
randomisaon, n = 917
Included in 
these analyses  
n = 917 
Diagnosed >6 mo 
prerandomisaon 
n = 59
Fig. 1 – Patient selection process for this newly diagnosed M1 control-
arm cohort analysis.
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The Systemic Therapy in Advancing or Metastatic Prostate
Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-
Arm Randomised Controlled Trial (STAMPEDE) started
recruiting in October 2005. It recruits men with either
newly diagnosed metastatic (M1), high-risk localised, or
node-positive (N+) prostate cancer (PCa). The trial tests the
addition of further treatments to androgen deprivation
therapy (ADT), including docetaxel, zoledronic acid, cele-
coxib, abiraterone, enzalutamide, and (among newly diag-
nosed M1 patients only) radiotherapy, using a multiarm,
multistage design. Research arms have recruited at over-
lapping times, but the control armhas been consistently ADT
alone and recruited throughout [1].
PCa is the second most common cancer worldwide
among men. With newer licensed therapies that prolong
survival in patients relapsing with metastatic castrate-
resistant prostate cancer (mCRPC) [2–9] and the increasingly
widespread use of prostate-specific antigen (PSA) testing,
men with M1 disease may have lower disease burden at
diagnosis than in the past. In this era of PSA testing and
effective therapies for patients with mCRPC, there are
limited, contemporary, long-termdata on the natural history
of newly diagnosed patients receiving ADT alone. Data from
older studies tend to quote median overall survival (OS)
times of 30–36 mo [2,3,10–12] and a median OS of around
18mo in the castrate-resistant setting. Given recent changes
to the management paradigm of mCRPC, it is timely to
explore current survival outcomes and treatment standards.
Nowthe largest therapeutic randomisedcontrolled trial in
PCa, the STAMPEDE trial’s control armprovides valuable data
on survival outcomes, prognostic factors, and subsequent
treatments for a prospective cohort of men with newly
diagnosed M1 disease receiving standard-of-care therapy.
This paper aims to describe survival outcomes for such men
and considers these in the context of similar groups in older
trials. We also investigate factors associated with prognosis
and describe subsequent treatments received following
disease progression.
2. Patients and methods
2.1. Overall trial recruitment and eligibility
Patients were recruited to the STAMPEDE trial from>100 sites across the
United Kingdom and Switzerland. To be eligible, patients must have PCathatwas either high-risk, newly diagnosed, nonmetastatic, node-negative
(N0) disease, newly diagnosed M1 or N+ disease, or disease (previously
treated with radical surgery and/or radiotherapy) that was rapidly
relapsing at the time of randomisation. The patients must have been
intended for treatment with long-term ADT started no longer than 12 wk
prior to randomisation, if at all. Baseline investigations must have been
completed prior to randomisation, including computed tomography (CT)
scan or magnetic resonance imaging (MRI) of the pelvis and abdomen,
bone scanor equivalent (eg,wholebodyMRI; chest radiograph, if the chest
was not included in the CT scan; orMRI), electrocardiogram, and PSA test.
Therewere no age restrictions, andpatients had tobeﬁt for chemotherapy
and have no signiﬁcant cardiovascular history.
2.2. Population of interest
For this prospective cohort analysis, we selected all men with newly
diagnosed (within 6mo prior to randomisation)metastatic PCawhowere
randomised to the control arm of the STAMPEDE trial between October
2005 and January 2014 (Fig. 1). All patients were planned for treatment
with standard-of-care ADT, according to local practice, which comprised[(Fig._1)TD$FIG]
Table 1 – Newly diagnosed M1 control-arm patient characteristics
at baseline
Patient level No. %
All 917 100
Metastases grouping
Bone-only 574 62
Soft-tissue * only 106 12
Bone and soft tissue* 237 26
Regional lymph node status
N0 292 32
N+ 545 59
NX 80 9
Bone-only metastases and regional lymph node status grouping
Bone and N0 276 54
Bone and N+ 233 46
Bone and NX 65 NA
Either soft tissue only or
bone and soft tissue
343 NA
Primary tumour stage
T2 93 10
T3 515 56
T4 232 25
TX 77 9
Initial Gleason-sum score category
7 156 17
8 587 64
Unknown 174 19
Age group, yr
<60 192 21
60–64 192 21
65–69 236 26
70 297 32
WHO performance statusy
0 662 72
1 and 2 255 28
PSA level at randomisation (prehormone therapy), ng/ml (quintile)
<26.6 (lowest) 184 20
26.9–72.0 183 20
72.3–160.0 (mid) 183 20
164.0–497.0 184 20
499.5 (highest) 183 20
PSA = prostate-speciﬁc antigen; WHO =World Health Organization.
* Soft tissue included distant lymph node (n = 277), liver (n = 19), and
lung (n = 40) metastases.
y WHO performance status is deﬁned as: 0: normal activity without
restriction; 1: strenuous activity restricted, can do light work; 2: up and
about >50% of waking hours, capable of self-care.
E U RO P E AN URO L OG Y 6 7 ( 2 0 1 5 ) 1 0 2 8 – 1 0 3 81030either orchidectomy or luteinising hormone-releasing hormone agonists
or antagonists, with or without long-term oral antiandrogens. Treatment
after disease progression was at the discretion of the consulting clinician.
2.3. Data collection
Baseline data included patient demographics, metastatic sites, regional
lymph node status, primary tumour stage, and diagnosis date. Details of
disease progression and subsequent treatments were obtained from
progression forms. Details of cardiovascular and acute renal events were
obtained from follow-up and serious adverse event forms. The protocol
can be found online [13]. The trial was registered both on clinicaltrials.gov
as NCT00268476 and on controlled-trials.com as ISRCTN78818544, had
the relevant regulatory and ethics approval, and all patients gave written,
informed consent.
2.4. Outcome measures
The trial’s deﬁnitive and intermediate primary outcome measures were
overall survival (OS) and failure-free survival (FFS) [14]; these outcome
measures formed the primary focus of this cohort analysis. Survival was
deﬁned as time from randomisation to death from any cause. FFS was
deﬁned as time from randomisation to evidence of at least one of the
following: biochemical failure; progression either locally, in lymph
nodes, or in distant metastases; or death from PCa.
Biochemical failure was deﬁned as failing at diagnosis (PSA nadir
>50% of the last pretreatment PSA level), 50% increase above nadir (PSA
nadir at least 50% lower than the last pretreatment PSA level but
remaining >4 ng/ml), or either a 50% increase from nadir or PSA level
>4 ng/ml (PSA nadir <4 ng/ml). The PSA nadir was taken as the lowest
PSA value reported in the ﬁrst 24 wk after randomisation.
Cause of death was determined by blinded central review. Death
from PCa was taken when classiﬁed by the reviewer as deﬁnitely or
probably PCa. The site investigator’s determination was used for deaths
not yet reviewed.
2.5. Subgroup definitions
Outcomes were deﬁned according to the following baseline groupings:
metastases grouping (bone only, soft tissue only, bone and soft tissue);
regional lymph node status (N0, N+, NX) and primary tumour stage
(T2, T3, T4, TX) at baseline; initial Gleason sum score category (7, 8,
unknown); age at randomisation (<60, 60–64, 65–69, 70 yr); World
Health Organization (WHO) performance status (0 vs 1 and 2); PSA level
measuredbefore startingADT(quintiles)andPSAnadir (<4,4). PSAnadir
wasonly calculable for those patients on trial for at least 26wkandwith at
least one documented follow-up PSA value in that time period. Coxmodel
reference groups were as follows: lowest grouping for regional lymph
nodes, Gleason score, WHO performance status, and PSA level; soft tissue
only formetastases; T3 for primary tumour stage (largest group); and 65–
69 yr for age group (contains cohort median age).
2.6. Statistical analyses
Analyses were performed using Stata v13 (StataCorp LP, College Station,
TX, USA) using standard survival-analysis methods. Kaplan-Meier
estimates were used to produce survival curves. Univariate and
multivariate Cox models explored the impact of predeﬁned subgroups.
Time-to-event analyses were calculated from randomisation to the
outcome of interest, with those not experiencing the event censored at
time of last contact, except PSA nadir, which used a landmark at 26 wk
postrandomisation to allow for the nadir to be calculated. The impact of
PSA nadir could not be examined for men with events or withdrawal of
consent prior to 26wk or insufﬁcient data up to 26wk.Median follow-up
was determined through reverse censoring on death.3. Results
The cohort selection process is shown in Figure 1. Of
5272 eligible patients randomised to the trial from October
2005 to January 2014, 1716 patients were allocated to the
control arm. Of these, 917 men had metastatic PCa newly
diagnosedwithin6mobefore randomisation. These917men
formthe cohort describedhere and constitute 17%ofpatients
joining the trial. Thedata setwas frozen in January2014,with
median follow-up of 20mo (interquartile range [IQR]: 6–37)
and total follow-up for all patients of 1449.7 yr.
3.1. Patient cohort
Table 1 shows thecohortbaseline characteristics (splitbyage
group in Supplementary Table 1). Median age at randomisa-
tion was 66 yr (IQR: 61–71), with 620 of 917 men (68%)
<70yrold.Median time fromPCadiagnosis to randomisation
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112 ng/ml (IQR: 34–373 ng/ml) before starting ADT and
median time onADTat randomisation of 46d (IQR: 24–66 d).
Of the 917 men, 906 (99%) reported their current course of
ADT as LHRH analogues or antagonists; where type was
available, 71% (319 of 449) reported LHRH agonist therapy.
The largest proportion of the cohort had bone-only
metastases (574 of 917; 62%); 106 of 917 (26%) had both
bone and soft tissue metastases; and 106 of 917 (12%) had
soft tissue–only metastases. Soft tissue metastasis was
overwhelmingly found in distant lymph nodes (n = 277;
30%),whereas relatively fewmenpresentedwithmetastases
in the liver (n = 19; 2%), lung (n = 40; 4%), or other sites
(n = 57; 6%). The low number of patients with visceral
metastases made separate analysis impractical. One-third of
patients (292 of 917) had no regional lymph node involve-
ment (N0).
3.2. Survival and failure-free survival outcomes
Of the 917 patients, 502 reported at least one FFS event and
238 had died. Median FFS for the cohort was 11.2 mo (IQR:
5.1–28.8 mo) and median OS was 42.1 mo (IQR: 22.7–90.7
mo). Two-year estimates for FFS and survival were 29% (95%
CI, 25–33), and 72% (95% CI, 68–76), respectively (Fig. 2).
Tables 2 and 3 show the relative impact of prognostic
factors on FFS and OS, respectively. In univariate models,
metastases groupingwas associatedwith both FFS andOS, as
were primary tumour stage, initial Gleason sum score
category, age group, and WHO performance status.
Figures 3 and 4 present Kaplan-Meier curves by metastases
grouping, WHO performance status, initial Gleason sum
score category, and age group, for FFS and OS, respectively.
Presence of bone metastases was associated with lower 2-yr
OS in men with soft tissue metastases, from 85% to 60%
(hazard ratio: 3.42; 95% CI, 1.96–5.97). Higher PSA level
before starting ADT and higher primary tumour stage[(Fig._2)TD$FIG]11.2 (IQR: 5.1–28
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Fig. 2 – Failure-free and overall survival for newly diagnosed M1 patients in th
FFS = failure-free survival; IQR = interquartile range.showed evidence of worsened FFS. In the subset of patients
with bone-only metastases, there was no evidence that
regional lymphnode involvementaffectedeitherFFSorOS. In
the landmark analysis of 457 patients with sufficient follow-
upandevent free at26wk,higherPSAnadir showedevidence
of worsened FFS; this was similar for OS in 644 patients with
sufficient follow-up and alive at 26 wk.
In multivariate models, presence of bone metastases
regardless of soft tissue metastases, worse WHO perfor-
mance status, higher or unknown initial Gleason sum score
category, and younger age at randomisation showed strong
evidence of both worsened FFS and OS after adjusting for
the other factors. Worsening primary tumour stage and
higher PSA level before starting ADT were both associated
with poorer FFS outcomes but not OS.
3.3. Cardiovascular and acute renal events
Cardiovascular causes were reported as primary cause of
death (COD) for seven patients; none had renal causes
reported as primary COD, although it was reported as
secondary COD for 11 patients (10 for whom PCa was
primary COD). With regard to worse toxicity grade reported
up to disease progression, seven patients had G3–4 cardiac
disorder and nine patients had G3–4 renal toxicity (Table 4).
3.4. Subsequent treatments and outcomes from progression
Supplementary Figure 1a shows the most frequent series of
subsequent therapies reportedatprogression (giveneither in
combination or independently over time), which were
bisphosphonate, chemotherapy, and abiraterone; no further
detail is reported here. Supplementary Figure 1b shows time
to subsequent therapy from first FFS event; all crossover/
subsequent treatments after initial treatment failure were
given at the investigator’s discretion. Of 502 patients
relapsing so far, 50% started chemotherapy within 16 mo42.1 (IQR: 22.7–90.7).8)
36 48 60
isation, mo
148 71(43) 20(30) (9)
50 25(28) 8(8) (3)
Deatht
e STAMPEDE trial control arm.
Table 2 – Newly diagnosed M1 control-arm patient characteristics at baseline and failure-free survival prognosis
Patient characteristics FFS
No. % Patient
level
FFS events,
no.
2-yr FFS
(95% CI)
Univariate HR *
(95% CI)
Overall
p value
Multivariate HR y
(95% CI)
Overall
p value
917 100 All 502 29 (25–33) – – – –
Metastases grouping
574 62 Bone only 320 28 (23–33) 2.22 (1.60–3.08) 2.06 (1.45–2.92)
106 12 Soft tissue only 42 54 (42–65) 1.00 1.00
237 26 Bone and soft tissue 140 18 (12–26) 2.84 (2.00–4.03) <0.001 2.41 (1.68–3.46) <0.001
Regional lymph node status
292 32 N0 156 31 (24–38) 1.00 1.00
545 59 N+ 295 29 (24–34) 0.93 (0.76–1.13) 0.95 (0.75–1.19)
80 9 NX 51 21 (12–33) 1.07 (0.77–1.47) 0.5637 0.86 (0.62–1.19) 0.6546
Bone-only metastases and regional lymph node status grouping
276 54 Bone and N0 150 30 (23–37) 1.00 NA
233 46 Bone and N+ 127 28 (20–35) 0.92 (0.72–1.17) 0.477 NA NA
65 NA Bone and NX
343 NA Either soft-tissue-only or bone and soft tissue
Primary tumour stage
93 10 T2 38 52 (39–63) 0.65 (0.47–0.92) 0.65 (0.46–0.92)
515 56 T3 284 27 (22–32) 1.00 1.00
232 25 T4 128 27 (19–35) 1.22 (0.99–1.50) 1.14 (0.92–1.42)
77 9 TX 52 24 (14–36) 1.52 (1.13–2.05) 0.0003 1.10 (0.81–1.51) 0.0262
Initial Gleason-sum score category
156 17 7 74 41 (31v51) 1.00 1.00
587 64 8 344 28 (24–33) 1.55 (1.21–2.00) 1.56 (1.20–2.02)
174 19 Unknown 84 16 (9–26) 1.92 (1.40–2.64) 0.0002 1.35 (0.96–1.89) 0.0030
Age group, yr
192 21 <60 137 18 (12–25) 1.53 (1.20–1.95) 1.59 (1.24–2.03)
192 21 60–64 105 28 (20–36) 1.11 (0.85–1.44) 1.14 (0.88–1.48)
236 26 65–69 123 32 (24–40) 1.00 1.00
297 32 70 137 36 (29–43) 0.96 (0.75–1.23) 0.0005 0.92 (0.72–1.17) 0.0001
WHO performance status§
662 72 0 353 31 (27–36) 1.00 1.00
255 28 1 and 2 149 22 (15–29) 1.51 (1.25–1.83) <0.001 1.37 (1.12–1.67) 0.002
PSA level at randomisation (prehormone therapy), ng/ml (quintiles)
184 20 <26.6 (lowest) 73 44 (34–53) 1.00 1.00
183 20 26.9–72.0 96 33 (24–42) 1.22 (0.90–1.66) 1.26 (0.92–1.71)
183 20 72.3–160.0 (mid) 101 31 (23–40) 1.37 (1.01–1.85) 1.40 (1.03–1.91)
184 20 164.0–497.0 121 19 (12–26) 1.88 (1.40–2.52) 1.63 (1.21–2.20)
183 20 499.5 (highest) 111 20 (13–28) 1.99 (1.47–2.68) <0.001 1.75 (1.27–2.41) 0.0052
PSA nadir #, ng/ml
357 78 <4 197 46 (40–52) 1.00 NA
100 22 4 72 26 (17– 37) 1.59 (1.21–2.08) 0.001 NA NA
225 NA On trial <26 wk
233 NA Progressed <26 wk
2 NA No follow-up PSA values
CI = conﬁdence interval; FFS = failure-free survival; HR = hazard ratio; NA = not applicable; PSA = prostate-speciﬁc antigen; WHO =World Health Organization.
* Cox models adjusted for age at randomisation as relevant.
y Cox models adjusted for all other variables.
§ WHO performance status is deﬁned as: 0: normal activity without restriction; 1: strenuous activity restricted, can do light work; 2: up and about >50% of
waking hours, capable of self-care.
# Analyses for PSA nadir were based on a landmark start time for patients of 6 mo; therefore, 2-yr survival is survival at 18 mo from the landmark.
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bisphosphonateandabiraterone,were reported startingafter
a longer time.
Of 502 patients with an FFS event, 230 died; median
follow-up time from FFS event was 22 mo. Median survival
from FFS event was also 22 mo, with 46% (95% CI, 40–51)
alive 2 yr after the first FFS event.
4. Discussion
Within this cohort of metastatic, newly diagnosed PCa
patients, treated only with ADT, we found median FFS to be
11.2 mo for the whole cohort from study entry, whereasmedian OS was 42.1 mo. For FFS and OS, respectively 29%
and 72% of patients were event free at 2 yr. Factors
prognostic of worsened outcome included presence of bone
metastases with or without soft tissue metastases, worse
WHO performance status, higher or unknown initial
Gleason sum score category, and younger age at randomi-
sation, for both FFS and OS. Worsening primary tumour
stage and higher PSA level before starting ADT were
associated with worsened FFS only. PSA nadir at 24 wk
was pertinent in the landmark analysis of patients who
were still responding to ADT at that time. Subsequent
therapies reported soonest on disease progression were
largely chemotherapy based.
Table 3 – Newly diagnosed M1 control-arm patient characteristics at baseline and overall survival prognosis
Patient characteristics Overall survival
No. % Patient
level
OS events,
no.
2-yr OS
(95% CI)
Univariate
HR*
(95% CI)
Overall
p value
Multivariate
HRy
(95% CI)
Overall
p value
917 100 All 238 72 (68–76) - – – –
Metastases grouping
574 62 Bone only 146 75 (69–79) 2.22 (1.34–3.69) 2.43 (1.41–4.19)
106 12 Soft-tissue only 17 85 (73–92) 1.00 1.00
237 26 Bone and soft tissue 75 60 (51–68) 3.22 (1.89–5.48) <0.001 3.42 (1.96–5.97) 0.0001
Regional lymph node status
292 32 N0 70 75 (68–81) 1.00 1.00
545 59 N+ 142 71 (65–76) 1.11 (0.83–1.48) 1.12 (0.80–1.59)
80 9 NX 26 70 (55–80) 1.17 (0.74–1.84) 0.7280 1.05 (0.66–1.69) 0.8004
Bone-only metastases and regional lymph node status grouping
276 54 Bone and N0 67 75 (67–81) 1.00 NA
233 46 Bone and N+ 58 74 (65–81) 1.13 (0.79–1.62) 0.492 NA NA
65 NA Bone and NX
343 NA Either soft tissue only or bone and soft tissue
Primary tumour stage
93 10 T2 19 75 (61–85) 0.78 (0.48–1.27) 0.81 (0.50–1.33)
515 56 T3 130 74 (69–79) 1.00 1.00
232 25 T4 57 69 (59–76) 1.17 (0.85–1.59) 1.17 (0.85–1.61)
77 9 TX 32 64 (49–76) 1.57 (1.06–2.32) 0.0589 1.16 (0.76–1.79) 0.5126
Initial Gleason-sum score category
156 17 7 36 81 (71–87) 1.00 1.00
587 64 8 159 70 (65–75) 1.60 (1.11–2.31) 1.68 (1.15–2.47)
174 19 Unknown 43 70 (59–79) 1.84 (1.17–2.88) 0.0178 1.43 (0.86–2.37) 0.0254
Age group, yr
192 21 <60 78 62 (53–70) 2.07 (1.44–2.99) 2.19 (1.50–3.19)
192 21 60–64 50 74 (64–81) 1.39 (0.93–2.09) 1.41 (0.94–2.13)
236 26 65–69 46 74 (65–81) 1.00 1.00
297 32 70 64 79 (71–84) 1.31 (0.90–1.92) 0.0007 1.22 (0.82–1.80) 0.0002
WHO performance status§
662 72 0 143 79 (75–83) 1.00 1.00
255 28 1 and 2 95 54 (45–61) 2.39 (1.84–3.10) <0.001 2.23 (1.70–2.93) <0.001
PSA level at randomisation (prehormone therapy), ng/ml (quintiles)
184 20 <26.6 (lowest) 41 74 (63–82) 1.00 1.00
183 20 26.9–72.0 48 70 (60–78) 0.97 (0.64–1.47) 1.01 (0.66–1.54)
183 20 72.3–160.0 (mid) 47 76 (66–83) 0.92 (0.60–1.40) 0.88 (0.56–1.36)
184 20 164.0–497.0 50 74 (65–81) 0.96 (0.63–1.45) 0.70 (0.45–1.09)
183 20 499.5 (highest) 52 67 (57–75) 1.22 (0.80–1.84) 0.6725 0.89 (0.56–1.41) 0.4739
PSA nadir#
412 64 <4 110 83 (78–86) 1.00 NA
232 36 4 107 59 (52–66) 2.43 (1.85–3.19) <0.001 NA NA
250 NA On trial <26 wk
20 NA Died <26 wk
3 NA No follow-up
PSA values
CI = conﬁdence interval; HR = hazard ratio; NA = not applicable; OS = overall survival; PSA = prostate-speciﬁc antigen; WHO =World Health Organization.
* Cox models adjusted for age at randomisation as relevant.
y Cox models adjusted for all other variables unless marked as NR (not relevant).
§ WHO performance status is deﬁned as: 0: normal activity without restriction; 1: strenuous activity restricted, can do light work; 2: up and about >50% of
waking hours, capable of self-care.
# Analyses for PSA nadir were based on a landmark start time for patients of 6 mo; therefore, 2-yr survival is survival at 18 mo from the landmark.
E U RO P E AN URO LOGY 6 7 ( 2 0 1 5 ) 1 0 2 8 – 1 0 3 8 1033These data suggest a relative improvement in survival
outcomes compared to older literature, but survival from
presentation with M1 PCa remains disappointing (Fig. 2).
The median OS reported here is longer than in the Phase III
Randomized Double-Blind Study of Clodronate versus
Placebo in Patients with Prostate Cancer Metastatic to
Bone Who Are Commencing or Responding to Initial
Hormone Therapy (MRC PR05; 28 mo) and SWOG Phase
III Trial Experience S8894 (33 mo) [11,12,15], shorter than
in the control arms of the Androgen-Deprivation Therapy
Alone or with Docetaxel in Noncastrate Metastatic ProstateCancer Trial (GETUG-15; 54 mo) and SWOG Phase III Trial
Experience S9346 (49 mo) [12,16], and similar to the 42 mo
presented for the control arm in the ChemoHormonal
Therapy versus Androgen Ablation Randomized Trial for
Extensive Disease in Prostate Cancer (CHAARTED) [17].
Inclusion criteria were not identical for these trials.
Data collected within our cohort allowed examination of
prognostic factors at presentation. Of particular interest
was the lack of detectable effect of regional lymph node
positivity as compared to distant node positivity on overall
prognosis. In particular, these data underscore the value of
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Fig. 3 – Failure-free survival by metastatic site, Gleason-sum score category, World Health Organisation performance status, and age at randomisation.
WHO PS =World Health Organization performance status.
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Fig. 4 – Overall survival by metastatic site, Gleason-sum score category, World Health Organization performance status, and age at randomisation.
WHO PS = World Health Organization performance status.
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Table 4 – Worst reported grade 3–4 cardiac disorder or renal
toxicity up to disease progression
No. Type of toxicity
Cardiac disorder
Grade 3 3 1 hypertension, 2 other (1 bradycardia,
1 angina)
Grade 4 4 2 MI, 2 other (aortic stenosis and
pulmonary embolism)
Missing 133 NA
Renal
Grade 3 8 2 renal failure, 1 haematuria, 1 renal
impairment, 4 other (3 urinary retention,
1 increased creatinine)
Grade 4 1 1 renal failure
Missing 132 NA
MI = myocardial infarction; NA = not applicable.
E U RO P E AN URO L OG Y 6 7 ( 2 0 1 5 ) 1 0 2 8 – 1 0 3 81036soft tissue imaging in patients presenting with a positive
bone scan, as concurrent presence of soft tissue metastasis
(mainly lymph nodes), in addition to bone metastases,
worsened 2-yr OS from 75% to 60%. Although uncommon,
soft tissue–only metastases had the most favourable
outcome, with 85% 2-yr OS. These effects were similar
whether the small proportion with visceral metastases was
omitted or included.
The finding that median OS is more than double the
median FFS demonstrates that the mCRPC phase nowmakes
up themajority of the survival time rather than being a short
terminal phase with limited treatment options. This is
consistent with the growing number of available therapies
for mCRPC. Indeed, our prospectively collected data were
drawn from men treated in the so-called docetaxel era.
Several newagentshavebeen licensed formCRPCsince2002,
including therapies such as docetaxel [2,3], cabazitaxel [4],
and abiraterone [5,7]; there are other new agents such as
enzalutamide [6], radium-223 [8], and sipuleucel-T [9] with
positive results but limited availability so far in this cohort. In
addition, there have been improvements in supportive care,
particularly formenwithbonymetastatic PCa,with licensing
of zoledronic acid [18,19] and denusomab [20,21]. Attitudes
in managing men with mCRPC have shifted from care with
palliative intent to active treatment using therapies improv-
ing survival and reducing morbidity.
The cohort of patients presented here should access
these new salvage options. Abiraterone has only been
widely available since 2011, with a licence extension to
the prechemotherapy population in 2013; hence, we would
expect to see changes in patterns of abiraterone use as the
data mature. With a similar extension of the licence to
pre-docetaxel patients pending for enzalutamide, this use is
also likely to change. Likewise, although all patients entering
the trialwere fit for chemotherapy, the reportedmedian time
from relapse to chemotherapy is estimated at 16 mo, with
time to the upper quartile not yet reached, suggesting a
significant proportion of patients will never receive chemo-
therapy. As drugs such as abiraterone (also an experimental
arm in the main trial) move into wider practice, we shall
examine the impact of salvage strategies on OS (Supplemen-
tary Fig. 1).The main strengths of our cohort include patients being
frommultiple centres with consistent, prospectively collect-
ed data and uniform standard-of-care treatment. However,
there are limitations. First, our substantive cohort was
drawn from the control arm of a clinical trial, inevitably
applying eligibility restrictions. This cohort was likely more
fit—due to exclusions for cardiovascular disease, men had
to be sufficiently fit to potentially receive chemotherapy
(to March 2013) and to have no significant cardiovascular
history [22] to potentially receive celecoxib (to April 2011
[22,23]—and younger than unselected men with newly
diagnosed metastatic PCa (median age was around 10 yr
below the median of the PCa population). Use of upfront
docetaxelmayhavedeterredolderpatients fromentering the
trial and may be one of the explanations for the low median
age of this cohort; age is often used inappropriately as a
surrogate for fitness. As our cohort may be less likely to die
from intercurrent illness, particularly cardiovascular, PCa
was the leading cause of death.
Second, our analyses are timed from randomisation
rather than diagnosis, making comparability against other
cohorts difficult, particularly single-centre series likely to
start from diagnosis. Patients were only eligible for
STAMPEDE if they were on ADT for no longer than 12 wk
before randomisation; most patients had been exposed to
6–8 wk of ADT before randomisation.
Third, median follow-upwithin this cohort is only 20mo;
recruitment was ongoing when this data set was frozen;
however,more than one-half of patients reported a FFS event
(502 of 917 men). Fourth, there may be underreporting of
treatments used after first progression, particularly for
treatments given later in the patient pathway.
The prognostic variables used within the multivariate
models were all pre-specified and we feel we used the best
disease predictors that we could identify in the data set
available. We acknowledge that the multivariate model is
likely incomplete. Laboratory values (including haemoglo-
bin, albumin, serum creatinine, and alkaline phosphatase
levels) were requested, but the completeness of the
necessary data to standardise these variables was lower
thanwewished toacceptandwewanted toavoid imputation
of missing values. These are likely important measures,
previously identified as prognostic factors in the Halabi
nomogram, albeit in CRPC patients [24]. We did not collect
dataonbonepain [25].Weanticipate thatWHOperformance
status (which we included in our analysis) may already
reflect the impact on general health from these other
variables.
Although using data from a trial’s control arm has
limitations, there is a need for a population-based prospec-
tive cohort study in this population to address questions
prospectively. No such study has been reported, and
construction of one would be at great financial cost while
taking many years to provide reliable long-term data. The
control arm of a high recruiting trial, such as STAMPEDE,
therefore provides high-quality prospective data for patients
receiving standard-of-care therapy in a hormone-naı¨ve
setting. It makes efficient use of the wealth of data collected
for the trial, incurring no extensive additional costs and
E U RO P E AN URO LOGY 6 7 ( 2 0 1 5 ) 1 0 2 8 – 1 0 3 8 1037simultaneously providing treatment safety and efficacy
answers. Also, our eligibility criteria were typical of clinical
trials in this therapy area, so these data are particularly
relevant to planning future studies in this population.
5. Conclusions
Survival outcomes in this large, multicentre cohort of men
with metastatic, newly diagnosed disease were shown to
have improved compared to previous reports in the
literature, although survival still remains disappointing for
this patient population. Subsequent therapies primarily
consisted of docetaxel alone or with other therapies. Factors
independently prognostic of shorter time to both disease
progression and death included younger age, presence of
bone metastases with or without soft tissue metastases, a
Gleason score category 8, and a WHO performance status
worse than zero. It is apparent that survival outcomes in this
setting still need to be greatly improved. The STAMPEDE trial
will prospectively report on eight treatment combinations
randomised against standard of care over 15 yr. Comparative
survival results should start to emerge from 2015.
The preliminary results of this study were presented at
the American Society of Clinical Oncology annual meeting
(ASCO 2013) in Chicago, IL, USA, and the 5th European
Multidisciplinary Meeting on Urological Cancers (EMUC
2013) in Marseille, France.
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